These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21690418)

  • 1. Two drugs approved for chronic hepatitis C infection.
    Traynor K
    Am J Health Syst Pharm; 2011 Jul; 68(13):1176. PubMed ID: 21690418
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapy of hepatitis C: new inhibitors as hammers against HCV].
    Bublak R
    MMW Fortschr Med; 2013 Jun; 155 Suppl 1():10-1. PubMed ID: 23961643
    [No Abstract]   [Full Text] [Related]  

  • 3. [Hepatitis C update: what has changed? What can we expect in the near future?].
    Geier A
    MMW Fortschr Med; 2013 Nov; 155(19):59-62. PubMed ID: 24475674
    [No Abstract]   [Full Text] [Related]  

  • 4. [New times for the treatment of chronic hepatitis C].
    Gerstoft J; Fomsgaard A
    Ugeskr Laeger; 2012 Mar; 174(12):795. PubMed ID: 22433552
    [No Abstract]   [Full Text] [Related]  

  • 5. HCV protease inhibitors bring new options for patients.
    Traynor K
    Am J Health Syst Pharm; 2011 Aug; 68(15):1372, 1374, 1379. PubMed ID: 21785015
    [No Abstract]   [Full Text] [Related]  

  • 6. Protease inhibitors in hepatitis C: from chronic disease to cure.
    Iqbal M; McCormick PA
    Ir Med J; 2011 Sep; 104(8):230-1. PubMed ID: 22125874
    [No Abstract]   [Full Text] [Related]  

  • 7. New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye.
    Dusheiko G; Wedemeyer H
    Gut; 2012 Dec; 61(12):1647-52. PubMed ID: 22936671
    [No Abstract]   [Full Text] [Related]  

  • 8. [A new era in therapy of hepatitis C: "the therapy can now be individualized" (interview by Dr. med. Dirk Einecke)].
    Manns M
    MMW Fortschr Med; 2011 Jul; 153(29-31):17. PubMed ID: 21830729
    [No Abstract]   [Full Text] [Related]  

  • 9. Infectious diseases. First specific drugs raise hopes for hepatitis C.
    Enserink M
    Science; 2011 Apr; 332(6026):159-60. PubMed ID: 21474720
    [No Abstract]   [Full Text] [Related]  

  • 10. Direct-acting antiviral (DAA) actions in treatment-naïve patients.
    Hézode C
    Clin Res Hepatol Gastroenterol; 2011 Dec; 35 Suppl 2():S52-8. PubMed ID: 22248695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on the use of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection.
    Fernández-Yunquera A; Rincón D; Salcedo M; Bañares R
    Rev Esp Quimioter; 2013 Sep; 26(3):189-92. PubMed ID: 24080883
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiviral agents and hepatitis C.
    Archer-Festa M; Nilsen-Kupsch S
    N Y State Dent J; 2012; 78(4):42-5. PubMed ID: 23252194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Future of antiviral therapy for chronic hepatitis C. Direct antiviral acting medications].
    Lange CM; Sarrazin C; Zeuzem S
    Pharm Unserer Zeit; 2011 Jan; 40(1):60-7. PubMed ID: 21194084
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of hepatitis C infection. A revolution should not hide another].
    Sogni P
    Presse Med; 2014 Apr; 43(4 Pt 1):339-40. PubMed ID: 24661837
    [No Abstract]   [Full Text] [Related]  

  • 15. The dilemma for patients with chronic hepatitis C: treat now or warehouse?
    Alberti A; Colombo M; Craxì A; Rizzetto M
    Dig Liver Dis; 2014 Jan; 46(1):27-9. PubMed ID: 24268949
    [No Abstract]   [Full Text] [Related]  

  • 16. Viral hepatitis C in 2014--the beginning of the end?
    Prelipcean CC; Gogălniceanu P; Mihai C
    Rev Med Chir Soc Med Nat Iasi; 2014; 118(2):272-8. PubMed ID: 25076687
    [No Abstract]   [Full Text] [Related]  

  • 17. Telaprevir and boceprevir: a potential role for therapeutic drug monitoring.
    Dolton MJ; Ray JE; McLachlan AJ
    Ther Drug Monit; 2013 Jun; 35(3):414-5. PubMed ID: 23670484
    [No Abstract]   [Full Text] [Related]  

  • 18. Update of the Belgian Association for the Study of the Liver guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors.
    Orlent H; Deltenre P; Francque S; Laleman W; Moreno C; Bourgeois S; Colle I; Delwaide J; De Maeght S; Mulkay JP; Stärkel P; Reynaert H;
    Acta Gastroenterol Belg; 2012 Jun; 75(2):245-59. PubMed ID: 22870791
    [No Abstract]   [Full Text] [Related]  

  • 19. The expanding role of the pharmacist in the management of hepatitis C infection.
    Spooner LM
    J Manag Care Pharm; 2011 Nov; 17(9):709-12. PubMed ID: 22050396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New agents for the treatment of hepatitis C].
    Buti M; Homs M
    Enferm Infecc Microbiol Clin; 2012 Mar; 30(3):147-50. PubMed ID: 22118805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.